Author Archives: Darren Marchal

The Far Reaches Of US Soft Power

The Russian ruble, Turkish lira, and Iranian rial are all falling in value. What do they have in common? The United States is in some way involved in their decline. It’s a sign of US power: Even as its military becomes more limited and it threatens to pull back from the Middle East and other…

3 Stocks To Buy Ahead Of Earnings

Stocks opened higher on Monday as investors seem to think the U.S.-led air strikes on Syria won’t lead to a much larger conflict. The strikes also coincided with the real start of first-quarter earnings season, which investors should use as a way to fight off the volatility that has plagued markets recently. Earnings season kicked into gear…

The Acronym Of 2008 Is Sounding Another Alarm

LIBOR, or the London Interbank Offered Rate, was the most important acronym most investors never heard of before 2008. However, it quickly became the most critical variable in markets leading up to the Great Recession. What has now become clear is that we haven’t learned any lessons from the financial crisis except how to accumulate…

Cracked Diamond

Hmmm. Things are looking less sanguine in bear-land. Although the SPY gap is still firmly intact, and has plenty of cushion left:   The Dow Industrials DIA has broken its descending trendline and exceeded its gap. Worrisome!  

Comments On The S&P And USD

(Audio length 00:10:49) Doc joins me today to shares his thoughts on the US markets and the USD. With daily volatility but no major breakouts in either direction, there are some levels we expect before the next bigger move. For the USD it continues to look weak but trade in a tighter range. Sounds like…

Palladium Rally Driving Other Metals Moves?

Many months ago we made an interesting call in Palladium and alerted to this setup on January 24th, 2018. This nearly perfect call included our future price expectations using our advanced ADL price modeling system. Today, we are refreshing that call with a new market call to inform you that our price prediction has played out…

Blueprint Sinks, Loxo Rises After Trial Data On Potential Solid T

Shares of Blueprint Medicines (BPMC) are sliding after the company reported data over the weekend regarding its early-stage candidate in RET-altered tumors. This morning, both Wedbush and JMP Securities raised their price targets on the stock, while Morgan Stanley analyst Matthew Harrison upgraded competitor Loxo Oncology (LOXO) to a buy-equivalent rating as he believes the…